查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040378

神經性疼痛市場規模、佔有率和趨勢分析報告：按藥物類別、適應症、給藥途徑、分銷管道、地區和細分市場預測（2026-2033 年）

Neuropathic Pain Market Size, Share & Trends Analysis Report By Drug Class,, By Indication, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

神經性疼痛市場概述

全球神經性疼痛市場預計在 2025 年達到 85.3 億美元，預計到 2033 年將達到 152.3 億美元，2026 年至 2033 年的複合年成長率為 7.58%。

神經病變疼痛市場的主要驅動力是全球慢性疾病負擔的加重，特別是糖尿病和癌症，這些疾病顯著增加了與神經損傷相關的疼痛疾病的盛行率。

糖尿病周邊神經病變仍是主要病因，印度和中國等新興經濟體糖尿病患者人數的持續成長也印證了這一點。例如，2025年4月，《自然》出版集團發表的一項研究表明，約50%的糖尿病患者會發展神經病變，盛行率在6%到60%以上不等。疼痛性糖尿病周邊神經病變影響13%至35%的患者，其中糖尿病患者的盛行率為13.3%，葡萄糖耐受不良患者為8.7%，空腹血糖異常患者為4.2%，糖耐受性正常患者為1.2%。此外，2024年10月，《內分泌學前沿》雜誌分析了4,908名患者，發現了1,627例。這代表了33.2%的盛行率，證實了全球對診斷和治療的需求日益成長。

另一個主要促進因素是治療格局的演變，其特點是轉向更安全、更具針對性的非鴉片類藥物療法。監管壓力和對鴉片類藥物濫用的日益重視導致鴉片類藥物依賴性降低，並加速了抗驚厥藥和抗憂鬱症的應用。由於局部療效、安全性和患者遵守用藥均有所提高，外用和經皮製劑的應用更加廣泛。製藥公司加大了對新型作用機制和聯合治療的投資，以提高療效並最大限度地減少副作用。脊髓刺激和經皮神經電刺激 (TENS) 等神經調控技術進一步擴展了治療選擇。例如，ScienceDirect 在 2025 年 1 月報告稱，神經性疼痛的盛行率在 3% 到 17% 之間，全球估計值約為 7% 到 8%。儘管治療方法眾多，但治療效果仍然有限，許多患者無法獲得充分的疼痛緩解，而醫療保健服務使用量的增加也推動了市場對更有效、更具創新性的治療方案的需求不斷成長。

醫療基礎設施、報銷體系和藥品可近性的改善，尤其是在新興地區，進一步推動了市場成長。在亞太地區和中東，醫療支出增加、保險覆蓋範圍擴大以及經濟實惠的學名藥供應量增加，提高了患者獲得神經性疼痛治療​​的機會。線上藥局和數位健康平台的興起促進了藥品分銷和患者用藥依從性，尤其對於需要長期管理的慢性病而言。政府針對非傳染性疾病的措施也有助於提高診斷和治療率。此外，製藥公司與醫療服務提供者之間的策略合作加強了病患教育和疾病管理實踐。這些發展共同縮小了治療差距，提高了治療可近性，並支持了市場的永續擴張。隨著醫療體系的現代化和公眾意識的提高，全球已開發地區和發展中地區的神經性疼痛市場均實現了穩定成長。

本報告預測了2021年至2033年全球、區域和國家層面的收入成長，並分析了各細分市場的最新產業趨勢。在本研究中，Grand View Research根據藥物類別、適應症、給藥途徑、分銷管道和地區對全球神經性疼痛市場報告進行了細分：

  • 特定藥物類別展望（銷售額，百萬美元，2021-2033 年）。
  • 抗驚厥藥物。
  • 抗憂鬱症。
  • 鴉片類藥物。
  • 外用藥物。
  • 依指標預測（銷售額，百萬美元，2021-2033 年）。
  • 糖尿病周邊神經病變。
  • 帶狀皰疹後遺症神經痛。
  • 化療引起的周邊神經病變。
  • HIV相關神經病變。
  • 三叉神經痛。
  • 中樞神經神經病變疼痛。
  • 其他。
  • 按管理途徑分類的預測（銷售額，百萬美元，2021-2033 年）。
  • 口服。
  • 僅供外用。
  • 注射用藥物。
  • 經皮。
  • 按分銷管道分類的銷售預測（收入，百萬美元，2021-2033 年）。
  • 醫院藥房。
  • 零售藥房。
  • 網上藥局。
  • 醫療機構和專科醫療中心。
  • 區域預測（收入，百萬美元，2021-2033 年）。
  • 北美。
    • 我們。
    • 加拿大。
    • 墨西哥。
  • 歐洲。
    • 英國。
    • 德國。
    • 法國。
    • 義大利.
    • 西班牙。
    • 丹麥。
    • 瑞典。
    • 挪威。
  • 亞太地區。
    • 日本。
    • 中國。
    • 印度。
    • 澳大利亞。
    • 韓國。
    • 泰國。
  • 拉丁美洲。
    • 巴西。
    • 阿根廷。
  • 中東和非洲。
    • 南非。
    • 沙烏地阿拉伯.
    • 阿拉伯聯合大公國.
    • 科威特。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 神經性疼痛市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：神經性疼痛市場：依藥物類別分類的商業分析

  • 按藥物類別分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按藥物類別分類，2021-2033 年
  • 抗驚厥藥物
  • 抗憂鬱症
  • 鴉片類藥物
  • 外用製劑

第5章：神經性疼痛市場：按適應症分類的業務分析

  • 按適應症分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按適應症分類，2021-2033 年
  • 糖尿病周邊神經病變
  • 帶狀皰疹後遺症神經痛
  • 化療引起的周邊神經病變
  • HIV相關神經病變
  • 三叉神經痛
  • 中樞神經神經病變疼痛
  • 其他

第6章：神經性疼痛市場：依給藥途徑進行業務分析

  • 按行政途徑分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按給藥途徑分類，2021-2033 年
  • 口服
  • 外用
  • 注射藥物
  • 經皮

第7章 神經性疼痛市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 醫療機構及專業醫療設施

第8章 神經性疼痛市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Pfizer Inc.
    • Eli Lilly and Company
    • Johnson & Johnson
    • Novartis AG
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie Inc.
    • Grunenthal GmbH
    • Daiichi Sankyo Company, Limited
Product Code: GVR-4-68040-885-4

Neuropathic Pain Market Summary

The global neuropathic pain market size was estimated at USD 8.53 billion in 2025 and is projected to reach USD 15.23 billion by 2033, growing at a CAGR of 7.58% from 2026 to 2033. The neuropathic pain market was primarily driven by the rising global burden of chronic diseases, particularly diabetes and cancer, which significantly increased the prevalence of nerve damage related pain conditions.

Diabetic peripheral neuropathy remained the largest contributor, supported by the steady growth of diabetic populations in emerging economies such as India and China. For instance, in April 2025, Nature Publishing Group published a study indicating that approximately 50% of diabetes patients developed neuropathy, with prevalence ranging from 6% to over 60%. Painful diabetic peripheral neuropathy affected 13% to 35% of patients, with prevalence at 13.3% in diabetes, 8.7% in impaired glucose tolerance, 4.2% in impaired fasting glucose, and 1.2% in normal glucose tolerance. In addition, in October 2024, Frontiers in Endocrinology analyzed 4,908 patients, identifying 1,627 cases, representing 33.2% prevalence, supporting expanding diagnosis and treatment demand globally.

Another key driver was the evolving treatment landscape, characterized by a shift toward safer, targeted, and non-opioid therapies. Regulatory pressure and rising awareness regarding opioid misuse reduced dependence on opioids, accelerating adoption of anticonvulsants and antidepressants. Topical and transdermal formulations gained traction due to localized action, improved safety, and better patient compliance. Pharmaceutical companies increasingly invested in novel mechanisms and combination therapies to enhance efficacy and minimize side effects. Neuromodulation technologies such as spinal cord stimulation and transcutaneous electrical nerve stimulation further expanded treatment options. For instance, in January 2025, ScienceDirect reported neuropathic pain prevalence between 3% and 17%, with global estimates around 7% to 8%. Despite available therapies, treatment outcomes remained moderate, with many patients experiencing inadequate relief and increased healthcare utilization, reinforcing demand for more effective and innovative therapeutic solutions in the market.

Market growth was further supported by improvements in healthcare infrastructure, reimbursement frameworks, and drug accessibility, particularly across emerging regions. Countries in Asia Pacific and the Middle East experienced rising healthcare expenditure, expanding insurance coverage, and increased availability of cost-effective generic medications, improving patient access to neuropathic pain treatments. The growth of online pharmacies and digital health platforms enhanced drug distribution and patient adherence, especially for chronic conditions requiring long-term management. Government initiatives targeting non-communicable diseases also contributed to improved diagnosis and treatment rates. In addition, strategic collaborations between pharmaceutical companies and healthcare providers strengthened patient education and disease management practices. These developments collectively reduced treatment gaps, increased therapy penetration, and supported sustained market expansion. As healthcare systems continued to modernize and awareness improved, the neuropathic pain market experienced steady growth across both developed and developing regions globally.

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neuropathic pain market report based on drug class, indication, route of administration, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Anticonvulsants
  • Antidepressants
  • Opioids
  • Topical Agents
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Diabetic Peripheral Neuropathy
  • Postherpetic Neuralgia
  • Chemotherapy-Induced Peripheral Neuropathy
  • HIV-Associated Neuropathy
  • Trigeminal Neuralgia
  • Central Neuropathic Pain
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Topical
  • Injectable
  • Transdermal
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Institutional & Specialty Centers
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Neuropathic Pain Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Neuropathic Pain Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2025 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 4.4. Anticonvulsants
    • 4.4.1. Anticonvulsants Market, 2021 - 2033 (USD Million)
  • 4.5. Antidepressants
    • 4.5.1. Antidepressants Market, 2021 - 2033 (USD Million)
  • 4.6. Opioids
    • 4.6.1. Opioids Market, 2021 - 2033 (USD Million)
  • 4.7. Topical Agents
    • 4.7.1. Topical Agents Market, 2021 - 2033 (USD Million)

Chapter 5. Neuropathic Pain Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 5.4. Diabetic Peripheral Neuropathy
    • 5.4.1. Diabetic Peripheral Neuropathy Market, 2021 - 2033 (USD Million)
  • 5.5. Postherpetic Neuralgia
    • 5.5.1. Postherpetic Neuralgia Market, 2021 - 2033 (USD Million)
  • 5.6. Chemotherapy-Induced Peripheral Neuropathy
    • 5.6.1. Chemotherapy-Induced Peripheral Neuropathy Market, 2021 - 2033 (USD Million)
  • 5.7. HIV-Associated Neuropathy
    • 5.7.1. HIV-Associated Neuropathy Market, 2021 - 2033 (USD Million)
  • 5.8. Trigeminal Neuralgia
    • 5.8.1. Trigeminal Neuralgia Market, 2021 - 2033 (USD Million)
  • 5.9. Central Neuropathic Pain
    • 5.9.1. Central Neuropathic Pain Market, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Neuropathic Pain Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2021 - 2033 (USD Million)
  • 6.5. Topical
    • 6.5.1. Topical Market, 2021 - 2033 (USD Million)
  • 6.6. Injectable
    • 6.6.1. Injectable Market, 2021 - 2033 (USD Million)
  • 6.7. Transdermal
    • 6.7.1. Transdermal Market, 2021 - 2033 (USD Million)

Chapter 7. Neuropathic Pain Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.7. Institutional & Specialty Centers
    • 7.7.1. Institutional & Specialty Centers Market, 2021 - 2033 (USD Million)

Chapter 8. Neuropathic Pain Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Neuropathic Pain Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Eli Lilly and Company
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Johnson & Johnson
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Novartis AG
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Viatris Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Teva Pharmaceutical Industries Ltd.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. AbbVie Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Grunenthal GmbH
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Daiichi Sankyo Company, Limited
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global neuropathic pain market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 5 Global neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 6 Global neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 7 Global neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 8 North America neuropathic pain market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 10 North America neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 11 North America neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 12 North America neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 U.S neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 14 U.S neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 15 U.S neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 16 U.S neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Canada neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 18 Canada neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 19 Canada neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 20 Canada neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 21 Mexico neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 22 Mexico neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 23 Mexico neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 24 Mexico neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 Europe neuropathic pain market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 27 Europe neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 28 Europe neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 29 Europe neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 UK neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 31 UK neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 32 UK neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 33 UK neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Germany neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 35 Germany neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 36 Germany neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 37 Germany neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 38 France neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 39 France neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 40 France neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 41 France neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Italy neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 43 Italy neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 44 Italy neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 45 Italy neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46 Spain neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 47 Spain neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 48 Spain neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 49 Spain neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 50 Norway neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 51 Norway neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 52 Norway neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 53 Norway neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Denmark neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 55 Denmark neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 56 Denmark neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 57 Denmark neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 Sweden neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 59 Sweden neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 60 Sweden neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 61 Sweden neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific neuropathic pain market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Japan neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 68 Japan neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 69 Japan neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 70 Japan neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71 China neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 72 China neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 73 China neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 74 China neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 India neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 76 India neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 77 India neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 78 India neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 79 Australia neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 80 Australia neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 81 Australia neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 82 Australia neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 83 South Korea neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 84 South Korea neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 85 South Korea neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 86 South Korea neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Thailand neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 88 Thailand neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 89 Thailand neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 90 Thailand neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 91 Latin America neuropathic pain market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 93 Latin America neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 94 Latin America neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 95 Latin America neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 96 Brazil neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 97 Brazil neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 98 Brazil neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 99 Brazil neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 100 Argentina neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 101 Argentina neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 102 Argentina neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 103 Argentina neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa neuropathic pain market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 108 Middle East & Africa neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 109 South Africa neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 110 South Africa neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 111 South Africa neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 112 South Africa neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 117 UAE neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 118 UAE neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 119 UAE neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 120 UAE neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 121 Kuwait neuropathic pain market, by drug class, 2021 - 2033 (USD Million)
  • Table 122 Kuwait neuropathic pain market, by indication, 2021 - 2033 (USD Million)
  • Table 123 Kuwait neuropathic pain market, by route of administration, 2021 - 2033 (USD Million)
  • Table 124 Kuwait neuropathic pain market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Neuropathic pain market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Neuropathic pain market dynamics
  • Fig. 11 Neuropathic pain market: Porter's five forces analysis
  • Fig. 12 Neuropathic pain market: PESTLE analysis
  • Fig. 13 Drug class market, 2021 - 2033 (USD Million)
  • Fig. 14 Anticonvulsants market, 2021 - 2033 (USD Million)
  • Fig. 15 Antidepressants market, 2021 - 2033 (USD Million)
  • Fig. 16 Opioids market, 2021 - 2033 (USD Million)
  • Fig. 17 Topical Agents market, 2021 - 2033 (USD Million)
  • Fig. 18 Indication market, 2021 - 2033 (USD Million)
  • Fig. 19 Diabetic Peripheral Neuropathy market, 2021 - 2033 (USD Million)
  • Fig. 20 Postherpetic Neuralgia market, 2021 - 2033 (USD Million)
  • Fig. 21 Chemotherapy-Induced Peripheral Neuropathy market, 2021 - 2033 (USD Million)
  • Fig. 22 HIV-Associated Neuropathy market, 2021 - 2033 (USD Million)
  • Fig. 23 Trigeminal Neuralgia market, 2021 - 2033 (USD Million)
  • Fig. 24 Central Neuropathic Pain market, 2021 - 2033 (USD Million)
  • Fig. 25 Others Agents market, 2021 - 2033 (USD Million)
  • Fig. 26 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 27 Oral market, 2021 - 2033 (USD Million)
  • Fig. 28 Topical market, 2021 - 2033 (USD Million)
  • Fig. 29 Injectable market, 2021 - 2033 (USD Million)
  • Fig. 30 Transdermal market, 2021 - 2033 (USD Million)
  • Fig. 31 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 32 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 33 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 34 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 35 Institutional & Specialty Centers market, 2021 - 2033 (USD Million)
  • Fig. 36 Neuropathic pain market revenue, by region
  • Fig. 37 Regional marketplace: Key takeaways
  • Fig. 38 North America Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. country dynamics
  • Fig. 40 U.S. Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 41 Canada country dynamics
  • Fig. 42 Canada Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 43 Mexico country dynamics
  • Fig. 44 Mexico Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 45 Europe Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 46 UK country dynamics
  • Fig. 47 UK Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 48 Germany country dynamics
  • Fig. 49 Germany Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 50 France country dynamics
  • Fig. 51 France Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 52 Italy country dynamics
  • Fig. 53 Italy Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 54 Spain country dynamics
  • Fig. 55 Spain Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 56 Norway country dynamics
  • Fig. 57 Norway Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 58 Sweden country dynamics
  • Fig. 59 Sweden Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 60 Denmark country dynamics
  • Fig. 61 Denmark Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 62 Asia Pacific Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 63 Japan country dynamics
  • Fig. 64 Japan Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 65 China country dynamics
  • Fig. 66 China Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 67 India country dynamics
  • Fig. 68 India Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 69 Australia country dynamics
  • Fig. 70 Australia Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 71 South Korea country dynamics
  • Fig. 72 South Korea Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 73 Thailand country dynamics
  • Fig. 74 Thailand Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 75 Latin America Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 76 Brazil country dynamics
  • Fig. 77 Brazil Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 78 Argentina country dynamics
  • Fig. 79 Argentina Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 80 MEA Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 81 South Africa country dynamics
  • Fig. 82 South Africa Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 83 Saudi Arabia country dynamics
  • Fig. 84 Saudi Arabia Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 85 UAE country dynamics
  • Fig. 86 UAE Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 87 Kuwait country dynamics
  • Fig. 88 Kuwait Neuropathic pain market, 2021 - 2033 (USD Million)
  • Fig. 89 Company categorization
  • Fig. 90 Company market position analysis
  • Fig. 91 Strategic framework